Lilly, Incyclix to work on Verzenio combo treatment for breast cancer
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Anchiy
- Eli Lilly (NYSE:LLY) and privately held Incyclix Bio have agreed to work on a clinical trial together evaluating the former’s Verzenio (abemaciclib) with the latter’s INX-315 and fulvestrant as a potential treatment for HR+/HER2- breast cancer.
- Terms call for Lilly to supply Verzenio while Incyclix is responsible for conducting the study, which will be in individuals who have progressed on a prior CDK4/6i regimen. Each company retains the commercial and development rights to each of their compounds.
- Verzenio is a CDK4/6 inhibitor while INX-315 is a CDK2 inhibitor.
- Separately, Incyclix is conducting a first-in-human, phase 1/2, open-label, dose escalation and dose-expansion study to evaluate the safety, PK, and preliminary antitumor activity of INX-315 in patients with advanced/metastatic cancers.